Sleep apnoea firm ResMed has joined with Google’s life science division Verily to form a new joint venture studying the health and financial impact of undiagnosed and untreated disease, and find new ways to treat it, reports Pharma Phorum.
The joint venture will combine ResMed’s expertise in sleep apnoea and Verily’s advanced health data analytics technologies.
As well as assessing the impact of untreated disease on patients’ lives, it will develop software to more efficiently identify, diagnose, treat, and manage patients with sleep apnoea and other breathing related sleep disorders.
Caused by the walls of the throat relaxing and narrowing during sleep and interrupting breathing, the disease affects around 54 million people in the US, and is associated with heart disease, stroke, type 2 diabetes and other life-threatening conditions.
